image

Immuno-Oncology

Innovative Drugs Designed to Improve Patients’ Lives

Nurix is advancing three internally discovered and wholly owned clinical-stage drug-candidates designed to treat patients with hematologic malignancies and solid tumors. Nurix’s pipeline comprises both Targeted Protein Degraders to eliminate disease causing proteins and E3 ligase inhibitors that target key control elements in immune regulation (Targeted Protein Elevation). Drug discovery alliances with Gilead Sciences and Sanofi further enhance our pipeline, each focusing on the discovery and development of Targeted Protein Degraders against a set of unique targets.

Building Immunity to Cancer: Nurix’s Immuno-Oncology Program

Targeted Protein Elevation: CBL-B Inhibition

Casitas B-lineage lymphoma proto-oncogene-b (CBL-B) is an E3 ligase that is expressed in immune cells and in the context of cancer, acts as a brake on the immune system. CBL-B functions as an intracellular checkpoint that negatively regulates T cell activation, NK cell activity, and immune response through degradation of specific proteins.

Conversely, inhibition of CBL-B with a small molecule drug activates T cells, a goal in the treatment of cancer, where T cells and the entire immune system can be mobilized to destroy a tumor. Nurix has developed two CBL-B inhibitors, NX-1607 for oral administration and NX-0255 for ex vivo use in combination with adoptive cell therapies such as tumor infiltrating lymphocytes (TIL) or chimeric antigen receptor T cells (CAR T).

Drug ProgramTarget/DeliveryTherapeutic AreaDiscoveryIND enablingPhase 1aPhase 1b
Targeted Protein Degradation
NX-2127 Degrader BTK + IKZF (Oral) B-cell malignancies

 

NX-5948 Degrader BTK (Oral) B-cell malignancies

 

NX-0479 / GS-6791 Degrader IRAK4 (Oral) Rheumatoid arthritis and other inflammatory diseases

 

Drug ProgramTarget/DeliveryTherapeutic AreaDiscoveryIND enablingPhase 1aPhase 1b
Targeted Protein Elevation
NX-1607 Inhibitor CBL-B (Oral) Immuno-oncology

 

Drug ProgramTarget/DeliveryTherapeutic AreaDiscoveryIND enablingPhase 1aPhase 1b
Discovery Pipeline
Wholly Owned 5 targets Undisclosed

 

Gilead Sciences 4 Targets Undisclosed

 

Sanofi 5 Targets Undisclosed

 

Targeted Protein Degradation
NX-2127 DegraderBTK + IKZF (Oral) - B-cell malignancies

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

NX-5948 DegraderBTK (Oral) - B-cell malignancies

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

NX-0479 / GS-6791 DegraderIRAK4 (Oral) - Rheumatoid arthritis and other inflammatory diseases

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

Targeted Protein Elevation
NX-1607 InhibitorCBL-B (Oral) - Immuno-oncology

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

Discovery Pipeline
Wholly Owned 5 targets - Undisclosed

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

Gilead Sciences4 Targets - Undisclosed

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

Sanofi5 Targets - Undisclosed

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

NX-1607 (oral CBL-B inhibitor for solid tumors)

NX-1607 is an oral, small molecule CBL-B inhibitor. In multiple preclinical animal models of both colorectal cancer and triple negative breast cancer, NX-1607 demonstrates anti-tumor activity and prolongs survival. The combination of NX-1607 with an anti-PD-1 antibody provides additional benefit in animal models. The anti-tumor activity of NX-1607 is dependent on both CD8+ T cells and NK cells.

We are planning to develop NX-1607 in multiple solid tumors and lymphoma as monotherapy or in combination with other complementary therapies such as anti-PD-1 antibodies. NX-1607 may also have utility in combination with cell therapies such as TIL or CAR T. A Phase 1 clinical trial of NX-1607 as a single agent therapy in multiple oncology indications is ongoing.